| Date | Title | | | 01/03/12 | AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial|
TIVO-1 is the First Registration Trial to Compare an Investigational
Agent to an Approved VEGF Therapy in First-line RCC
AVEO Conference Call Today at 8:30 a.m. ET
CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Jan. 3, 2012--
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE:
4503) today announced that tivozanib demonstrated superiority over
sorafenib in the primary endpoint of progression-free survival (PFS) in
... |
|  | | 01/02/12 | AVEO Pharmaceuticals, Inc. Announces Webcast and Conference Call| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2012-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Tuesday, January 3, 2012 at 8:30 a.m. (ET). The call can be accessed by dialing 1-866-825-3354 (domestic) or 1-617-213-8063 (international) five minutes prior to the start of the call and providing the passcode 17542026. A replay of the call will be available approximately two hours after the completion of the call and can be acc... |
| | | 12/28/11 | AVEO Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 28, 2011--
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan
Ha-Ngoc, president and chief executive officer, is scheduled to present
at the 30th Annual J.P. Morgan Healthcare Conference on
Tuesday, January 10, 2012 at 11:30 a.m. (PST) at the Westin St. Francis
Hotel in San Francisco.
A live webcast of AVEO’s presentation can be accessed by visiting the
investors section of the c... |
| |
|
